The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
S. W. Yee, C. Macdonald, D. Mitrovic, X. Zhou, M. Koleske, J. Yang, D. B. Silva, P. R. Grimes, D. Trinidad, S. S. More, L. Kachuri, J. S. Witte, L. Delemotte, K. M. Giacomini, W. Coyote-Maestas
Abstract
Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients not responding to the recommended dosage of drug whereas others experience catastrophic side effects. For example, variants within the major hepatic Human organic cation transporter OCT1 (SLC22A1) can change endogenous organic cations and many prescription drug levels. To understand how variants mechanistically impact drug uptake, we systematically study how all known and possible single missense and single amino acid deletion variants impact expression and substrate uptake of OCT1. We find that human variants primarily disrupt function via folding rather than substrate uptake. Our study revealed that the major determinants of folding reside in the first 300 amino acids, including the first 6 transmembrane domains and the extracellular domain (ECD) with a stabilizing and highly conserved stabilizing helical motif making key interactions between the ECD and transmembrane domains. Using the functional data combined with computational approaches, we determine and validate a structure-function model of OCT1s conformational ensemble without experimental structures. Using this model and molecular dynamic simulations of key mutants, we determine biophysical mechanisms for how specific human variants alter transport phenotypes. We identify differences in frequencies of reduced function alleles across populations with East Asians vs European populations having the lowest and highest frequency of reduced function variants, respectively. Mining human population databases reveals that reduced function alleles of OCT1 identified in this study associate significantly with high LDL cholesterol levels. Our general approach broadly applied could transform the landscape of precision medicine by producing a mechanistic basis for understanding the effects of human mutations on disease and drug response.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Insights into the structure and function of the human organic anion transporter 1 in lipid bilayer membranes
A. Janaszkiewicz, A. Toth, … F. Di Meo·Scientific ReportsPeer-reviewed·Apr 29, 2022
- Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2
Y. Suo, N. J. Wright, … S.-Y. Lee·bioRxiv·Mar 15, 2023
- Functional characterization of six SLCO1B1 (OATP1B1) variants observed in Finnish individuals with a psychotic disorder
Katja Häkkinen, Wilma Kiander, … the SUPER-Finland researchers listed in the Acknowledgements·Molecular PharmaceuticsPeer-reviewed·Feb 13, 2023
- Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale
A. Janaszkiewicz, A. Toth, … F. Di Meo·bioRxiv·Jul 14, 2022
- Structural basis of organic cation transporter-3 inhibition
B. Khanppnavar, J. Maier, … H. H. Sitte·bioRxiv·Jul 14, 2022
- Accelerated Molecular Dynamics and AlphaFold Uncover a Missing Conformational State of Transporter Protein OxlT
J. Ohnuki, T. Jaunet-Lahary, … K.-i. Okazaki·bioRxiv·Oct 26, 2023